Posted inClinical Updates Dermatology news
Skin-Specific Outcomes of Brepocitinib in Dermatomyositis: Evidence from a Phase 3 Randomized Clinical Trial and Secondary Analysis
Brepocitinib, a selective TYK2-JAK1 inhibitor, showed rapid, sustained skin disease control, itch relief, and improved quality of life in dermatomyositis patients over 52 weeks with an acceptable safety profile in a global phase 3 trial.